122 results on '"PSOTKA, MITCHELL"'
Search Results
2. Framework of the Strengths and Challenges of Clinically Integrated Trials: An Expert Panel Report
3. Contemporary approach to cardiogenic shock care: a state-of-the-art review
4. Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?
5. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
6. Rethinking heart failure clinical trials: the heart failure collaboratory
7. Treatment Effects Of Empagliflozin In Hospitalized Heart Failure Patients Across The Range Of Left Ventricular Ejection Fraction - Results From The EMPULSE Trial
8. Variation Of Prespecified Subgroups In Large-Scale HF Outcome Trials
9. Advanced heart disease
10. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
11. UNCOMMON BUT NOT UNSEEN: A RARE CAUSE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
12. BILIRUBIN ELEVATION AND OUTCOMES IN EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) SUPPORT
13. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE
14. Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
15. The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse
16. Advanced Practice Provider Urgent Outpatient Clinic for Patients With Decompensated Heart Failure
17. AN UNCOMMON CAUSE OF HEART FAILURE: ACROMEGALIC CARDIOMYOPATHY CULMINATING IN ORTHOTOPIC HEART TRANSPLANTATION
18. UTILIZATION OF GUIDELINE DIRECTED MEDICAL THERAPY FOR HEART FAILURE IN CARDIOGENIC SHOCK SURVIVORS: AN INOVA SHOCK REGISTRY ANALYSIS
19. A SMOKED HEART: CORONARY ARTERY SPASM AND CARDIOGENIC SHOCK DUE TO ACUTE CARBON MONOXIDE POISONING
20. Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice
21. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study
22. Functional and Symptomatic Clinical Trial Endpoints
23. The evolving landscape of pulmonary arterial hypertension clinical trials
24. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
25. A Standardized and Regionalized Network of Care for Cardiogenic Shock
26. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
27. Wearables in Cardiovascular Disease
28. Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results from The Empulse Trial
29. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
30. Expenditure on Heart Failure in the United States
31. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
32. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
33. CMV Infection Following mRNA SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
34. Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes
35. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials
36. Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension
37. The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction
38. Exploring Physician Perceptions of the 2018 United States Heart Transplant Allocation System
39. Predicting Cardiac Structural And Functional Improvement On Left Ventricular Assist Device Support: The Externally Validated UCAR Score
40. Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies
41. IS IT TIME TO UPDATE THE CLASSIFICATION OF HEART FAILURE AS HEART FAILURE WITH OR WITHOUT EVIDENCE OF SYSTOLIC DYSFUNCTION?
42. FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL
43. EMPAGLIFLOZIN IN PATIENTS HOSPITALIZED FOR DE NOVO VERSUS DECOMPENSATED CHRONIC HEART FAILURE: INSIGHTS FROM THE EMPULSE TRIAL
44. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
45. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
46. Proteomic differences among patients with heart failure taking furosemide or torsemide
47. LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events
48. Quality of Life Always Matters
49. Abstract 12124: A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study
50. Abstract 13324: One-Year Outcomes in Patients With Cardiogenic Shock: Insights From the Inova-Shock Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.